Poolbeg Pharma PLC
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| POLB.L | ACTI.ST | CGEN | ATORX.ST | COCP | NBP | |
|---|---|---|---|---|---|---|
| Market cap | 47.64M | 102.54M | 192.29M | 38.89M | 19.46M | 117.16M |
| P/E (TTM) | — | — | 5.3 | — | — | — |
| Forward P/E | -10.6 | — | -5.5 | -0.1 | -2.1 | -0.8 |
| Price/book | 6.2 | 2.8 | 2.2 | 0.3 | 13.3 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +75.34% | −34.67% | +23.78% | −99.41% | +2.88% | −76.29% |
| Today | −2.50% | +5.71% | +1.00% | +1.87% | −5.61% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All POLB.L news ›Poolbeg Pharma's Korean patent grant bolsters Cavendish’s ‘buy’ case
Proactive has a commercial relationship with Poolbeg Pharma PLC. This article was produced independently under Proactive's Editorial Standards Policy. Poolbeg Pharma PLC (AIM:POLB) secured a South Korean patent for POLB 001, with Cavendish…
Poolbeg Pharma secures South Korean patent for POLB 001
Poolbeg Pharma (POLB) has secured a South Korean patent covering POLB 001 and the use of p38 MAP kinase inhibitors to prevent cancer immunotherapy associated cytokine release syndrome (CRS). The patent, entitled “Medicinal products and…
More from 1 other outlet
Poolbeg Pharma secures South Korean patent for cancer therapy side effect prevention
Poolbeg Pharma has obtained a South Korean patent for POLB 001, a treatment designed to prevent cytokine release syndrome (CRS), a serious side effect of cancer immunotherapy. The patent covers the use of p38 MAP kinase inhibitors to…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- pluang.com2
- businesspost.ie1
- proactiveinvestors.com1
- voxmarkets.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.